Pricing Log in Create free account
Friday 6 November 2026 Export TXG’s income statement to Excel — free account

10x Genomics

TXG Healthcare Medical Devices

10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.

Revenue
+1.12%
EPS
+31.8%
Free cash flow
−4.61%

Quarter to September 2026, against a year earlier

57.62 0.44 −0.76%
Market cap
$7.6B
P/E
0.0×
Fwd P/E
−95.9×
Dividend yield
—
F-score
6/9
Altman Z
3.99
Beneish M
−3.23
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

10x Genomics (TXG) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 3 added · 2 removed · 26 modified
P2I1A: no comparison — low extraction confidence 		Receivables outpacing revenue
8-K Nov 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 28, 2026 5.02 Departure or appointment of directors or officers Officer departure
10-Q Jun 30, 2026 P1I2: 11 added · 4 removed · 21 modified
P2I1A: no comparison — incorporated by reference
8-K Aug 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 4, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 2 added · 1 removed · 21 modified
1A: 20 added · 5 removed · 110 modified
7: 26 added · 8 removed · 43 modified
8-K Feb 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 11, 2026 2.02 Results of operations and financial condition
8-K Nov 12, 2025 5.02 Departure or appointment of directors or officers
10-Q Sep 30, 2025
8-K Nov 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 6, 2025 2.02 Results of operations and financial condition; 2.05 Costs of exit or disposal activities; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 12, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 12, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 24, 2024 2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K Oct 9, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 6, 2024 2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Apr 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 15, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.